Healthcare Stocks Update: DaVita HealthCare Partners (DVA), ACADIA Pharmaceuticals (ACAD)


DaVita HealthCare Partners Inc (NYSE:DVA)

Stock’s Trading Stats:

DaVita HealthCare Partners Inc (NYSE:DVA) declined -0.60% yesterday and closed at $73.03. The company’s market capitalization is at $14.95Billion with an average trading volume of 1.03 Million. The total number of Outstanding Shares Held by the company are 209.75Million.

Recent Press Release:

DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. (DVA) and a leading provider of kidney care services, on March 23, 2016 declared the launch of an upgraded and customized online experience for registered myDaVita users.

The upgraded version of myDaVita provides registered users with a customized dashboard for those with chronic kidney disease (CKD), those on dialysis and caregivers based on their connection to kidney disease. Additional tools and ease of navigation have been improved, allowing users to find what they are looking for quickly and easily.

Anyone can join myDaVita by visiting myDaVita and registering for the free, online community, gaining access to various customizable tools and resources dedicated to those affected by kidney disease.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Stock’s Trading Stats:

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) closed at $29.90 yesterday by showing a decrease of -0.53%. The total number of outstanding shares held by the company are 112.64 Million with the total market capitalization of $3.53billion. The number of shares traded on the last trading session are 3.20 Million.

Recent Press Release:

ACADIA Pharmaceuticals Inc. (ACAD) on March 29, 2016 declared that NASDAQ has halted trading of the company’s common stock.

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) is meeting recently to review NUPLAZID™ (pimavanserin) for the treatment of patients with psychosis associated with Parkinson’s disease.

The Committee is an independent panel of experts that reviews and evaluates data regarding the safety and effectiveness of marketed and investigational human drug products for use in the practice of psychiatry and related fields and makes appropriate recommendations to the FDA.

According to the National Parkinson Foundation, about one million people in the United States and from four to six million people worldwide suffer from Parkinson’s disease. An estimated 40 percent of these patients have Parkinson’s disease psychosis, which is characterized by hallucinations and delusions, a diminished quality of life, and noteworthy caregiver burden.